Grossberger, O., Sherban, A., Amitai, I., Hellmann, I., Nachmias, B., Wolach, O., Moshe, Y. (2025). Disease status at initiation of blinatumomab and depth of response after cycle 1 are associated with survival in Philadelphia chromosome positive B cell acute lymphoblastic leukemia patients treated with blinatumomab and tyrosine kinase inhibitors. Blood. https://doi.org/10.1182/blood-2025-3321